

Elazar Rabbani et al.  
Serial No. 08/978,635  
Filed: November 25, 1997  
Page 2 (Amendment In Connection With Notice To Comply With Sequence Rules -  
June 8, 1998)

**REMARKS**

By this Amendment applicants are directing the entry of the initial paper copy of the accompanying "Sequence Listing" into the instant specification, thereby conforming with one of the requirements of the Notice To Comply With Sequence Listing.

No fee is believed due in connection with this Amendment. If any fee or fees are due, however, the Patent and Trademark Office is hereby authorized to charge the amount of any such fee to Deposit Account 05-1135, or to credit any overpayment thereto.

If helpful to processing this Amendment, the undersigned may be contacted by telephone at (212) 583-0100 during the daytime hours.

Respectfully submitted,



Ronald C. Fedus  
Registration No. 32,567  
Attorney for Applicants

ENZO THERAPEUTICS, INC.  
c/o Enzo Biochem, Inc.  
527 Madison Avenue (9<sup>th</sup> Fl.)  
New York, New York 10022  
(212) 583-0100

LC/USProsecution/Enz53\enz53(d4)\amendment\sequencerrules 060898 3enz53D4

**ENZ-53(D4)**

Elazar Rabbani et al.  
Serial No.: 08/574,443  
Filed: Herewith  
Page: 4 (Request for a Continuation Application Under 37 C.F.R. 1.60 -  
November 25, 1997)

Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Nov 25 97  
Date



Signature [Ronald C. Fedus]  
Registration No. 32, 567  
Attorney for Applicants  
 Inventor(s)  
 Assignee of Complete Interest  
 Attorney or Agent of Record  
 Filed under 37 CFR 1.34(a)

Address of Signator:  
Enzo Therapeutics, Inc.  
c/o Enzo Biochem, Inc.  
527 madison Avenue (9th Floor)  
New York, New York 10022